MOLN - Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences | Benzinga
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA. In addition, members of Molecular Partners' leadership team will participate in upcoming investor events in Switzerland during January 2024.
Conference Presentation Details
The 42nd Annual J.P. Morgan Healthcare Conference
Presenter: Patrick Amstutz, Ph.D. Chief Executive Officer
Time: Thursday, January 11, 2024 at 11:15 am/ ET (5:15 pm CET)
Location: San Francisco, CA
Baader Helvea Swiss Equities Conference
Presenter: Alexander Zürcher, Chief Operating Officer
Time: Wednesday, January 10, 2024 at 10:30am ET (4:30pm CET)
Location: Bad Ragaz, Switzerland
Conference Participation Details
The Octavian Seminar
January 11-13, 2024
Location: Davos, Switzerland
All webcast presentations will be made available on the Molecular Partners website.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and infectious disease and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.